Baseline Immunological Profile in Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial

被引：0
|
作者：
Mao-Draayers, Yang [2 ]
Wu, Qi
Wang, Qin
Dowling, Catherine
Lundy, Steven [3 ,4 ]
Segal, Benjamin [2 ]
Wallstrom, Wallstrom [1 ]
机构：
[1] Novartis Pharma AG, Basel, Switzerland
[2] Univ Michigan, Dept Neurol, Ann Arbor, MI USA
[3] Univ Michigan, Sch Med, Dept Internal Med, Div Rheumatol, Ann Arbor, MI USA
[4] Univ Michigan, Sch Med, Dept Neurol, Ann Arbor, MI USA
来源：
NEUROLOGY | 2016年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P3.046
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Magnetization Transfer Imaging in Secondary Progressive Multiple Sclerosis Patients Treated with Siponimod: Results from the Phase 3 EXPAND Study
    Arnold, Douglas L.
    Cree, Bruce A. C.
    Bar-Or, Amit
    Giovannoni, Gavin
    Gold, Ralf
    Vermersch, Patrick
    Meier, Daniela Piani
    Arnould, Sophie
    Ritter, Shannon
    Karlsson, Goeril
    Kappos, Ludwig
    Fox, Robert
    [J]. NEUROLOGY, 2020, 94 (15)
  • [32] Baseline Characteristics in the Tolebrutinib Phase 3 Non-Relapsing Secondary Progressive Multiple Sclerosis (nrSPMS) HERCULES Clinical Trial
    Fox, Robert J.
    Bar-Or, Amit
    Traboulsee, Anthony
    Oreja-Guevara, Celia
    Giovannoni, Gavin
    Vermersch, Patrick
    Dukovic, Deborah
    Vargas, Wendy S.
    Syed, Sana
    Turner, Timothy
    Reich, Daniel
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 938 - 939
  • [33] Safety and efficacy of siponimod in patients with active secondary progressive multiple sclerosis identifying as Hispanic from the phase 3 EXPAND study
    Cohan, S.
    Hua, L. H.
    Bar-Or, A.
    Lublin, F. D.
    Meng, X.
    Cox, G. M.
    Coyle, P. K.
    Fox, R. J.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 590 - 591
  • [34] The lymphocyte subpopulation in patients with primary progressive multiple sclerosis and secondary progressive multiple sclerosis
    Belniak, Ewa
    Bojarska-Junak, Agnieszka
    Bartosik-Psujek, Halina
    Mitosek-Szewezyk, Krystyna
    Kulka, Malgorzata
    Stelmasiak, Zbigniew
    Rolinski, Jacek
    [J]. MULTIPLE SCLEROSIS, 2008, 14 : S116 - S116
  • [35] Efficacy and safety of siponimod in secondary progressive multiple sclerosis - Results of the placebo controlled, double-blind, Phase III EXPAND study.
    Kappos, L.
    Bar-Or, A.
    Cree, B.
    Fox, R.
    Giovannoni, G.
    Gold, R.
    Vermersch, P.
    Arnould, S.
    Sidorenko, T.
    Wolf, C.
    Wallstroem, E.
    Dahlke, F.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 828 - 829
  • [36] The cladribine trial in secondary progressive multiple sclerosis: A reanalysis
    Beutler, E
    Koziol, JA
    [J]. NEUROEPIDEMIOLOGY, 2000, 19 (02) : 109 - 112
  • [37] A phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis
    Kita, M
    Goodkin, DE
    Bacchetti, P
    Stone, J
    Waubant, E
    Pelletier, D
    Nelson, SJ
    [J]. NEUROLOGY, 2000, 54 (07) : A22 - A23
  • [38] A phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis
    Kita, M
    Cohen, JA
    Fox, RJ
    Evangelista, A
    Pelletier, D
    Stone, J
    Goodkin, DE
    Zamvil, SS
    [J]. NEUROLOGY, 2004, 62 (07) : A99 - A99
  • [39] A phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis
    Kita, M
    Pelletier, D
    Goodkin, D
    Fox, R
    Cohen, J
    Bacchetti, P
    Stone, J
    Hietpas, J
    Zamvil, S
    [J]. NEUROLOGY, 2001, 56 (08) : A149 - A149
  • [40] Efficacy of Siponimod in secondary progressive multiple sclerosis patients with active disease: the EXPAND study subgroup analysis
    Gold, R.
    Kappos, L.
    Bar-Or, A.
    Vermersch, P.
    Giovannoni, G.
    Fox, R.
    Rouyrre, N.
    Karlsson, G.
    Cree, B. A. C.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 380 - 381
12345